細胞表麵都有，這樣免疫係統就不會攻擊健康細胞。不健康，衰老細胞CD47減少，或沒有，於是就會被正常免疫吞噬。

CD4在2020年有不少文章。主要是癌症領域！沒想到，COVID19逃過免疫吞噬的機製，竟然和癌症共通。

COVID19，莫名其妙地有了開啟人體細胞的鑰匙“SPIKE”

COVID19，對某些人（老人，高糖高血壓。。。）可以躲過免疫吞噬，劇烈複製，最終太多了觸發免疫風暴。殺死宿主。

COVID19的變異能力也是神級的，現在SPIKE可以稍微變化，導致針對SPIKE的防線漏洞百出。

真是病毒之神！

麵對神一樣的對手，明智的學者不會將雞蛋都放在SPIKE一個籃子裏，風險過高。如果最終出現完全的逃逸，怎麽辦？應該看看免疫過程的其他環節了！

 

 

 

 

CD47 is an immunoglobulin that is overexpressed on the surface of many types of cancer cells. CD47 forms a signaling complex with signal-regulatory protein α (SIRPα), enabling the escape of these cancer cells from macrophage-mediated phagocytosis. In recent years, CD47 has been shown to be highly expressed by various types of solid tumors and to be associated with poor patient prognosis in various types of cancer. A growing number of studies have since demonstrated that inhibiting the CD47-SIRPα signaling pathway promotes the adaptive immune response and enhances the phagocytosis of tumor cells by macrophages. Improved understanding in this field of research could lead to the development of novel and effective anti-tumor treatments that act through the inhibition of CD47 signaling in cancer cells. In this review, we describe the structure and function of CD47, provide an overview of studies that have aimed to inhibit CD47-dependent avoidance of macrophage-mediated phagocytosis by tumor cells, and assess the potential and challenges for targeting the CD47-SIRPα signaling pathway in anti-cancer therapy.

所有跟帖： 

• 既然CD47都有，IVM會清除所有？包括正常細胞？ -tryyyyyy- ♂ (0 bytes) () 09/28/2021 postreply 08:53:09

• 癌症治療也遇到同樣問題，劑量，和其他治療條件，必須配合。尋求一個平衡。確切地說，幾乎所有的要都要尋求一個平衡， -楓林曉- ♂ (0 bytes) () 09/28/2021 postreply 08:59:09

• 這和廣譜化療藥相似？權衡化不化的利弊？ -tryyyyyy- ♂ (0 bytes) () 09/28/2021 postreply 09:12:48

• 那要看，病毒感染的Cell如何反應，單獨用IVM，是一定要控製劑量的。在癌症上，如果大劑量使用，需要配合immune check -楓林曉- ♂ (0 bytes) () 09/28/2021 postreply 09:31:00